Recruiting for Restructuring: Target Schools, Internships, Timeline

Introduction

Restructuring recruiting is the most accelerated, most selective, and most concentrated segment of investment banking recruiting in the United States. The major restructuring practices (PJT Partners' RSSG, Houlihan Lokey's Financial Restructuring, Evercore Restructuring, Lazard Restructuring, and Moelis Restructuring) hire small classes from a narrow set of target schools through processes that begin in sophomore year and close before most peers have started looking. Candidates who do not understand the timing miss the cycle entirely.

This article walks through:

Restructuring recruiting follows the broader bulge-bracket and elite-boutique IB calendar but runs slightly tighter. For a Summer 2027 internship, the cycle effectively runs from April 2025 through December 2025, with the most consequential windows in September-November 2025.

The pace is striking. Many Rx interns receive their offers 18-24 months before they actually start the internship. PJT, Evercore, and Lazard often complete their summer analyst classes by September or October of sophomore spring, meaning the entire selection process happens before most candidates have even taken corporate finance.

The Rx recruiting universe is more concentrated than even bulge-bracket M&A recruiting. The major firms recruit primarily from:

PJT RSSG, Houlihan Lokey FR, and Lazard Restructuring tilt heavily toward Tier 1 and 2; Evercore and Moelis maintain slightly broader recruiting reach. Houlihan Lokey is somewhat known for being the most accessible of the major Rx firms for candidates from Tier 2 and 3 schools, given its larger overall analyst class and West Coast roots (Los Angeles HQ, with offices nationally).

The "target school" effect is most acute at PJT. The firm's RSSG hires approximately 8-10 analysts globally per year, and the program receives applications from essentially the entire target-school universe plus motivated candidates from beyond. The acceptance rate runs below 1% at PJT RSSG, which is among the lowest acceptance rates of any investment banking program in the U.S.

Target School

An undergraduate institution from which a particular investment bank actively recruits, typically by hosting on-campus information sessions, sending recruiters for first-round interviews, and maintaining standing alumni networks. Target schools differ by firm and by group. For Rx specifically, the target list is narrower than for general M&A, with the most selective firms (PJT RSSG, Lazard Rx) drawing primarily from a tier of fewer than fifteen schools.

The major restructuring firms run distinct recruiting processes worth understanding individually.

PJT Partners RSSG: 8-10 analysts and a sub-1% acceptance rate

PJT operates on an accelerated boutique calendar. Recruitment for Summer 2027 ran on a rolling basis from early September to mid-November 2026, with first-round interviews in October and offers extended by December. PJT requires candidates to choose Restructuring versus Strategic Advisory at application, so an Rx-focused candidate cannot apply broadly and decide later. The interview process is heavy on technical questions including bankruptcy law concepts, capital structure analysis, and recovery waterfalls.

Houlihan Lokey Financial Restructuring: largest class, broadest geographic reach

Houlihan Lokey runs the largest Rx analyst class among elite firms, typically approximately 15-25 analysts annually across U.S. offices (with roughly 10-12 in New York). The recruiting process is somewhat less time-accelerated than PJT's, and the firm has a reputation for being more accessible to non-traditional candidates with strong technical preparation. Houlihan's geographic distribution (offices in Los Angeles, New York, Chicago, San Francisco, Atlanta, Dallas) creates more analyst slots than the more concentrated New York-based competitors.

Evercore Restructuring: 8-10 specialists with M&A-heavy interviews

Evercore's Rx practice is smaller than its M&A practice (analyst class roughly 8-10 Rx specialists per year). The interview process emphasizes M&A fundamentals plus Rx-specific topics; candidates often interview for both groups and indicate preference late in the process.

Lazard Restructuring: small, prestige-driven, regulated-industry depth

Lazard runs one of the most prestigious Rx franchises with deep regulated-industry capabilities (utilities, healthcare, sovereigns). The analyst class is small (20-30 annually) and competition is intense. Interview questions tend to test breadth across both M&A and Rx fundamentals.

Moelis Restructuring: aggressive, meritocratic culture

Moelis & Company hires 15-25 Rx analysts per year, with a culture often described as more aggressive and meritocratic than peers. Interview processes emphasize quick technical thinking and direct engagement with senior interviewers.

Networking matters more in Rx recruiting than in most IB segments because the analyst classes are small and HR functions less centralized. The recommended approach involves:

1. Identify 10-15 alumni at each target firm through LinkedIn and school career services databases. 2. Request informational interviews in fall of sophomore year, framing the request as learning about the group rather than asking for a referral. 3. Build a dialogue across multiple touchpoints (initial coffee chat, follow-up question, application notice) before requesting a formal referral. 4. Demonstrate technical preparation in conversations by asking informed questions about recent cases, market structure, and the firm's specific positioning. 5. Target second-year analysts who have recent experience with the recruiting process and are most likely to provide candid advice.

The most effective candidates approach networking as relationship-building over months rather than transactional outreach close to the application deadline.

Across the major firms, the strongest Rx candidates share several characteristics:

The distressed credit interest signal is particularly important. Candidates who can articulate genuine interest in the dynamics of distressed companies, capital structure analysis, and creditor-versus-equity dynamics differentiate from candidates who simply want a brand-name boutique offer.

For candidates who miss the on-cycle window or come from non-target backgrounds, several pathways remain viable. Off-cycle internships in Rx are rare but possible, especially at smaller advisory firms (Greenhill, Guggenheim, Perella Weinberg). Lateral moves from M&A coverage groups into Rx happen occasionally, typically after the analyst's first year, with success depending on Rx group capacity and individual fit.

The most common alternative pathway is to start in M&A or leveraged finance at a strong firm, then lateral into Rx as an associate or move into a distressed credit hedge fund directly. The next thirteen articles in this section walk through each of those alternatives, the firms that dominate each segment, and the specific positioning that maximizes the probability of landing a strong Rx-related role across the full career arc.